Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Genprex Inc (GNPX) USD0.001

Sell:$3.95 Buy:$4.01 Change: $0.03 (0.75%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Sell:$3.95
Buy:$4.01
Change: $0.03 (0.75%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Sell:$3.95
Buy:$4.01
Change: $0.03 (0.75%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).

Contact details

Address:
1601 Trinity St Bldg B
AUSTIN
78712-1765
United States
Telephone:
+1 (512) 5377997
Website:
https://www.genprex.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GNPX
ISIN:
US3724461047
Market cap:
$171.38 million
Shares in issue:
43.28 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • J. Rodney Varner
    Chairman of the Board, President, Chief Executive Officer, Secretary
  • Ryan Confer
    Chief Financial Officer
  • Michael Redman
    Chief Operating Officer, Executive Vice President
  • Catherine Vaczy
    Executive Vice President, Chief Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.